OTLK's logo.
Ticker Symbol: OTLK

Outlook Therapeutics Inc

$2.00 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001649989

Company Profile

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 4260 U.S. Route 1
CEO: Lawrence Kenyon
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.23
Change: $0.01 ( 6.26%)
Days Range: $0.21 - $0.23
Beta: 0.64
52wk. High: $2.02
52wk. Low: $0.20
Ytd. Change -73.03%
50 Day Moving Average: $0.25
200 Day Moving Average: $1.13
Shares Outstanding: 260245017

Valuation

Market Cap: 6.2B
PE Ratio: -0.24
EPS (TTM): -0.9995

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A